I in renal cancer patients probably related to survival increase. There are few data in literature about the role of BPs in the treat- ment of bone disease from colorectal cancer. We present the pre- liminary data of a large Italian multicenter retrospective analysis. Methods. 284 renal cancer patients with evidence of bone metastases have been included in the study at the moment of ab- stract submission. Patients characteristics, skeletal related events (SRE) data and median survival after bone metastases appear- ance have been collected in a master data base and statistically analyzed. The primary efficacy endpoint was time to first SRE; secondary endpoint was median survival. Results. A total of 284 patients have been included for zole- dronic efficacy analysis. A total of 130 patients received zole- dronic acid (4 mg) via a 15-minute infusion every 4 weeks until performance status worsening or death. 154 patients have been analysed as control group. The median time to first SRE in the whole population was 1 month (0-72). The median time to first SRE in the zoledronic treated patients was 3 months (0-101) compared with 1 month (0-22) in the control group (p <0.05). The median survival after skeletal progression was 12 (1-178). The median survival in the zoledronic treated group was 15 months (2-120) compared with 7 months (1-178). (p <0.05). On- ly 2 cases of ONJ have been diagnosed. Conclusions. Complete results of statistical analysis will be presented during the meeting. The present analysis represents a confirmation, in clinical practice scenario, of zoledronic acid ac- tivity in bone metastases in renal cancer patients.
Tonini, G., Lanzetta, G., Silvestris, N., Tanca, F., Mazzara, C., Virzi, V., et al. (2011). EFFICACY OF ZOLEDRONIC ACID IN PATIENTS WITH RENAL CANCER METASTATIC TO BONE. In XII National Congress of Medical Oncology (pp.130-131).
EFFICACY OF ZOLEDRONIC ACID IN PATIENTS WITH RENAL CANCER METASTATIC TO BONE
BADALAMENTI, Giuseppe;
2011-01-01
Abstract
I in renal cancer patients probably related to survival increase. There are few data in literature about the role of BPs in the treat- ment of bone disease from colorectal cancer. We present the pre- liminary data of a large Italian multicenter retrospective analysis. Methods. 284 renal cancer patients with evidence of bone metastases have been included in the study at the moment of ab- stract submission. Patients characteristics, skeletal related events (SRE) data and median survival after bone metastases appear- ance have been collected in a master data base and statistically analyzed. The primary efficacy endpoint was time to first SRE; secondary endpoint was median survival. Results. A total of 284 patients have been included for zole- dronic efficacy analysis. A total of 130 patients received zole- dronic acid (4 mg) via a 15-minute infusion every 4 weeks until performance status worsening or death. 154 patients have been analysed as control group. The median time to first SRE in the whole population was 1 month (0-72). The median time to first SRE in the zoledronic treated patients was 3 months (0-101) compared with 1 month (0-22) in the control group (p <0.05). The median survival after skeletal progression was 12 (1-178). The median survival in the zoledronic treated group was 15 months (2-120) compared with 7 months (1-178). (p <0.05). On- ly 2 cases of ONJ have been diagnosed. Conclusions. Complete results of statistical analysis will be presented during the meeting. The present analysis represents a confirmation, in clinical practice scenario, of zoledronic acid ac- tivity in bone metastases in renal cancer patients.File | Dimensione | Formato | |
---|---|---|---|
XIII_Congresso_AIOM_Abstract_Book.pdf
accesso aperto
Dimensione
5.27 MB
Formato
Adobe PDF
|
5.27 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.